Our findings are consistent with those of He et al., who reported that tetrandrine, a TPC2 antagonist, increased MHC-I expression and IFN-γ secretion in melanoma, thereby enhancing responsiveness to PD-1 blockade (21). The gene discussed is IFNG; the disease is melanoma.